EVOTEC SE ADR 1/2 O.N. (EVTA) - Total Liabilities
Based on the latest financial reports, EVOTEC SE ADR 1/2 O.N. (EVTA) has total liabilities worth €900.24 Million EUR (≈ $1.05 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
EVOTEC SE ADR 1/2 O.N. - Total Liabilities Trend (2021–2025)
This chart illustrates how EVOTEC SE ADR 1/2 O.N.'s total liabilities have evolved over time, based on quarterly financial data. See EVOTEC SE ADR 1/2 O.N. (EVTA) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
EVOTEC SE ADR 1/2 O.N. Competitors by Total Liabilities
The table below lists competitors of EVOTEC SE ADR 1/2 O.N. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Henan Senyuan Electric Co Ltd
SHE:002358
|
China | CN¥3.73 Billion |
|
Capital City Bank Group
NASDAQ:CCBG
|
USA | $3.89 Billion |
|
Hudson Pacific Properties Inc
NYSE:HPP
|
USA | $4.31 Billion |
|
Besalco Sa
SN:BESALCO
|
Chile | CL$1.05 Trillion |
|
Pegavision
TW:6491
|
Taiwan | NT$4.44 Billion |
|
Yonyou Auto Information Technology (Shanghai) Co. Ltd.
SHG:688479
|
China | CN¥203.97 Million |
|
Gilat Satellite Networks Ltd
TA:GILT
|
Israel | ILA220.97 Million |
|
E&R Engineering
TWO:8027
|
Taiwan | NT$1.49 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down EVOTEC SE ADR 1/2 O.N.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see EVOTEC SE ADR 1/2 O.N. market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.53 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how EVOTEC SE ADR 1/2 O.N.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for EVOTEC SE ADR 1/2 O.N. (2021–2025)
The table below shows the annual total liabilities of EVOTEC SE ADR 1/2 O.N. from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €900.24 Million ≈ $1.05 Billion |
-6.22% |
| 2024-12-31 | €959.98 Million ≈ $1.12 Billion |
-15.24% |
| 2023-12-31 | €1.13 Billion ≈ $1.32 Billion |
+5.84% |
| 2022-12-31 | €1.07 Billion ≈ $1.25 Billion |
+24.79% |
| 2021-12-31 | €857.48 Million ≈ $1.00 Billion |
-- |
About EVOTEC SE ADR 1/2 O.N.
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammati… Read more